{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T23:23:45Z","timestamp":1773876225332,"version":"3.50.1"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100031816","name":"Narayana Nethralaya Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031816","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mutation Research - Genetic Toxicology and Environmental Mutagenesis"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.mrgentox.2025.503903","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T16:46:10Z","timestamp":1764261970000},"page":"503903","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The potential implications of dysregulated DNA damage repair genes and their modulators as adjuvants for current chemotherapy regimens in Retinoblastoma tumors"],"prefix":"10.1016","volume":"908","author":[{"given":"Keya","family":"Katare","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arkasubhra","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9824","key":"10.1016\/j.mrgentox.2025.503903_bib1","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/S0140-6736(11)61137-9","article-title":"Retinoblastoma","volume":"379","author":"Dimaras","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.mrgentox.2025.503903_bib2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3892\/ol.2022.13312","article-title":"Genome maintenance in retinoblastoma: Implications for therapeutic vulnerabilities","volume":"23","author":"Lee","year":"2022","journal-title":"Oncol. Lett."},{"issue":"5","key":"10.1016\/j.mrgentox.2025.503903_bib3","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/jamaoncol.2019.6716","article-title":"Global Retinoblastoma Presentation and Analysis by National Income Level","volume":"6","author":"Global Retinoblastoma Study","year":"2020","journal-title":"JAMA Oncol."},{"issue":"8","key":"10.1016\/j.mrgentox.2025.503903_bib4","doi-asserted-by":"crossref","first-page":"e1128","DOI":"10.1016\/S2214-109X(22)00250-9","article-title":"The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries","volume":"10","author":"Global Retinoblastoma Study","year":"2022","journal-title":"Lancet Glob. Health"},{"issue":"1","key":"10.1016\/j.mrgentox.2025.503903_bib5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41433-018-0244-7","article-title":"Retinoblastoma in Asia","volume":"33","author":"Jain","year":"2019","journal-title":"Eye (Lond. )"},{"issue":"9","key":"10.1016\/j.mrgentox.2025.503903_bib6","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.ophtha.2021.01.024","article-title":"Incidence of Retinoblastoma Has Increased: Results from 40 European Countries","volume":"128","author":"Stacey","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.mrgentox.2025.503903_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2024.101107","article-title":"Incidence, mortality, and global burden of retinoblastoma in 204 countries worldwide from 1990 to 2021: Data and systematic analysis from the Global Burden of Disease Study 2021","volume":"60","author":"Wang","year":"2025","journal-title":"Neoplasia"},{"issue":"2","key":"10.1016\/j.mrgentox.2025.503903_bib8","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/bjophthalmol-2015-306672","article-title":"Clinical presentation and survival of retinoblastoma in Indian children","volume":"100","author":"Chawla","year":"2016","journal-title":"Br. J. Ophthalmol."},{"issue":"3","key":"10.1016\/j.mrgentox.2025.503903_bib9","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3109\/13816810.2013.867450","article-title":"Outcomes of Intra- and Extraocular Retinoblastomas from a Single Institute in South India","volume":"36","author":"Shah","year":"2015","journal-title":"Ophthalmic Genet"},{"issue":"4","key":"10.1016\/j.mrgentox.2025.503903_bib10","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4103\/sajc.sajc_179_16","article-title":"Long-term follow-up of retinoblastoma survivors: Experience from India","volume":"6","author":"Seth","year":"2017","journal-title":"South Asian J. Cancer"},{"issue":"2","key":"10.1016\/j.mrgentox.2025.503903_bib11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0161-6420(96)30706-9","article-title":"Quantification of orbital and mid-facial growth retardation after megavoltage external beam irradiation in children with retinoblastoma","volume":"103","author":"Imhof","year":"1996","journal-title":"Ophthalmology"},{"issue":"14","key":"10.1016\/j.mrgentox.2025.503903_bib12","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/jnci\/85.14.1121","article-title":"Mortality from second tumors among long-term survivors of retinoblastoma","volume":"85","author":"Eng","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.mrgentox.2025.503903_bib13","first-page":"216","article-title":"Plaque radiotherapy in the management of retinoblastoma","volume":"100","author":"Shields","year":"1993","journal-title":"Use a Prim. Second. Treat. Ophthalmol."},{"issue":"2","key":"10.1016\/j.mrgentox.2025.503903_bib14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/13816818709028523","article-title":"The use of iodine-125 plaques in the treatment of retinoblastoma","volume":"8","author":"Stannard","year":"1987","journal-title":"Ophthalmic Paediatr. Genet"},{"key":"10.1016\/j.mrgentox.2025.503903_bib15","first-page":"128","article-title":"beta-Irradiation of retinoblastoma with 106Ru\/106Rh applicators","volume":"18","author":"Lommatzsch","year":"1977","journal-title":"Mod. Probl. Ophthalmol."},{"issue":"1","key":"10.1016\/j.mrgentox.2025.503903_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IAE.0000000000001275","article-title":"Ocular Pharmacology of Chemotherapy for Retinoblastoma","volume":"37","author":"Schaiquevich","year":"2017","journal-title":"Retina"},{"issue":"2","key":"10.1016\/j.mrgentox.2025.503903_bib17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/eye.2012.175","article-title":"Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy","volume":"27","author":"Shields","year":"2013","journal-title":"Eye (Lond. )"},{"key":"10.1016\/j.mrgentox.2025.503903_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.696787","article-title":"Safety and Efficacy of Intravitreal Chemotherapy (Melphalan) to Treat Vitreous Seeds in Retinoblastoma","volume":"12","author":"Yousef","year":"2021","journal-title":"Front Pharm."},{"issue":"9","key":"10.1016\/j.mrgentox.2025.503903_bib19","article-title":"Vincristine in Combination Therapy of Cancer: Emerging Trends in Clinics","volume":"10","author":"Skubnik","year":"2021","journal-title":"Biol. (Basel)"},{"key":"10.1016\/j.mrgentox.2025.503903_bib20","article-title":"DNA Repair Pathways in Cancer Therapy and Resistance","volume":"11","author":"Li","year":"2020","journal-title":"Front Pharm."},{"issue":"5","key":"10.1016\/j.mrgentox.2025.503903_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26931","article-title":"Clinical and genetic associations for carboplatin-related ototoxicity in children treated for retinoblastoma: A retrospective noncomparative single-institute experience","volume":"65","author":"Soliman","year":"2018","journal-title":"Pedia Blood Cancer"},{"issue":"7","key":"10.1016\/j.mrgentox.2025.503903_bib22","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.ophtha.2007.03.074","article-title":"Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor?","volume":"114","author":"Gombos","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.mrgentox.2025.503903_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.822330","article-title":"Treatment of Retinoblastoma: What Is the Latest and What Is the Future","volume":"12","author":"Schaiquevich","year":"2022","journal-title":"Front Oncol."},{"issue":"10","key":"10.1016\/j.mrgentox.2025.503903_bib24","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1634\/theoncologist.12-10-1237","article-title":"Retinoblastoma: review of current management","volume":"12","author":"Chintagumpala","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.mrgentox.2025.503903_bib25","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2147\/OTT.S370878","article-title":"Spotlight on Targeted Chemotherapy in Retinoblastoma: Safety, Efficacy, and Patient Outcomes","volume":"15","author":"Naseripour","year":"2022","journal-title":"Onco Targets Ther."},{"issue":"6","key":"10.1016\/j.mrgentox.2025.503903_bib26","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/archophthalmol.2011.5","article-title":"Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience","volume":"129","author":"Gobin","year":"2011","journal-title":"Arch. Ophthalmol."},{"issue":"22","key":"10.1016\/j.mrgentox.2025.503903_bib27","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1002\/cncr.27563","article-title":"Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity","volume":"118","author":"Qaddoumi","year":"2012","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.mrgentox.2025.503903_bib28","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1159\/000509080","article-title":"Intravitreal Melphalan for Retinoblastoma: The Impact of Toxicity on Recurrence and Ultimate Globe Salvage","volume":"6","author":"Berry","year":"2020","journal-title":"Ocul. Oncol. Pathol."},{"issue":"39","key":"10.1016\/j.mrgentox.2025.503903_bib29","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1038\/onc.2012.615","article-title":"DNA damage associated with mitosis and cytokinesis failure","volume":"32","author":"Hayashi","year":"2013","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.mrgentox.2025.503903_bib30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2165\/00002018-200629030-00005","article-title":"Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile","volume":"29","author":"Hartmann","year":"2006","journal-title":"Drug Saf."},{"issue":"7696","key":"10.1016\/j.mrgentox.2025.503903_bib31","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature25480","article-title":"The landscape of genomic alterations across childhood cancers","volume":"555","author":"Grobner","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.mrgentox.2025.503903_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/srep25264","article-title":"Somatic genomic alterations in retinoblastoma beyond RB1 are rare and limited to copy number changes","volume":"6","author":"Kooi","year":"2016","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.mrgentox.2025.503903_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040754","article-title":"Whole-Genome Sequencing of Retinoblastoma Reveals the Diversity of Rearrangements Disrupting RB1 and Uncovers a Treatment-Related Mutational Signature","volume":"13","author":"Davies","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7381","key":"10.1016\/j.mrgentox.2025.503903_bib34","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nature10733","article-title":"A novel retinoblastoma therapy from genomic and epigenetic analyses","volume":"481","author":"Zhang","year":"2012","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.mrgentox.2025.503903_bib35","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/gcc.20457","article-title":"One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma","volume":"46","author":"Corson","year":"2007","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"10.1016\/j.mrgentox.2025.503903_bib36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/ceo.12132","article-title":"The genomic landscape of retinoblastoma: a review","volume":"42","author":"Theriault","year":"2014","journal-title":"Clin. Exp. Ophthalmol."},{"issue":"8","key":"10.1016\/j.mrgentox.2025.503903_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26083523","article-title":"Retinoblastoma: Molecular Evaluation of Tumor Samples, Aqueous Humor, and Peripheral Blood Using a Next-Generation Sequence Panel","volume":"26","author":"Mendes","year":"2025","journal-title":"Int J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.mrgentox.2025.503903_bib38","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ophtha.2019.12.005","article-title":"Next-Generation Sequencing of Retinoblastoma Identifies Pathogenic Alterations beyond RB1 Inactivation That Correlate with Aggressive Histopathologic Features","volume":"127","author":"Afshar","year":"2020","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.mrgentox.2025.503903_bib39","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s42003-024-06596-6","article-title":"A MYCN-driven de-differentiation profile identifies a subgroup of aggressive retinoblastoma","volume":"7","author":"Ryl","year":"2024","journal-title":"Commun. Biol."},{"issue":"22","key":"10.1016\/j.mrgentox.2025.503903_bib40","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1101\/gad.288282.116","article-title":"RB localizes to DNA double-strand breaks and promotes DNA end resection and homologous recombination through the recruitment of BRG1","volume":"30","author":"Velez-Cruz","year":"2016","journal-title":"Genes Dev."},{"issue":"6","key":"10.1016\/j.mrgentox.2025.503903_bib41","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.molcel.2014.01.032","article-title":"Suppression of genome instability in pRB-deficient cells by enhancement of chromosome cohesion","volume":"53","author":"Manning","year":"2014","journal-title":"Mol. Cell"},{"issue":"2","key":"10.1016\/j.mrgentox.2025.503903_bib42","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jss.2007.03.038","article-title":"RB activity alters checkpoint response and chemosensitivity in lung cancer lines","volume":"142","author":"Reed","year":"2007","journal-title":"J. Surg. Res"},{"issue":"11","key":"10.1016\/j.mrgentox.2025.503903_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078641","article-title":"RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs","volume":"8","author":"Robinson","year":"2013","journal-title":"PLoS One"},{"issue":"7115","key":"10.1016\/j.mrgentox.2025.503903_bib44","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature05194","article-title":"Inactivation of the p53 pathway in retinoblastoma","volume":"444","author":"Laurie","year":"2006","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.mrgentox.2025.503903_bib45","doi-asserted-by":"crossref","first-page":"a012575","DOI":"10.1101\/cshperspect.a012575","article-title":"DNA repair by reversal of DNA damage","volume":"5","author":"Yi","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"4","key":"10.1016\/j.mrgentox.2025.503903_bib46","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nrc1319","article-title":"MGMT: its role in cancer aetiology and cancer therapeutics","volume":"4","author":"Gerson","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.mrgentox.2025.503903_bib47","first-page":"1344","article-title":"Impaired expression and promotor hypermethylation of O6-methylguanine-DNA methyltransferase in retinoblastoma tissues","volume":"43","author":"Choy","year":"2002","journal-title":"Invest Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.mrgentox.2025.503903_bib48","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s12253-012-9498-8","article-title":"Epigenetic and copy number variation analysis in retinoblastoma by MS-MLPA","volume":"18","author":"Livide","year":"2012","journal-title":"Pathol. Oncol. Res"},{"issue":"3","key":"10.1016\/j.mrgentox.2025.503903_bib49","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000048769","article-title":"Promoter methylation status of the DNA repair genes hMLH1 and MGMT in gastric carcinoma and metaplastic mucosa","volume":"69","author":"Oue","year":"2001","journal-title":"Pathobiology"},{"issue":"2","key":"10.1016\/j.mrgentox.2025.503903_bib50","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1349-7006.2002.tb01257.x","article-title":"Inactivation of O6-methylguanine-DNA methyltransferase in human lung adenocarcinoma relates to high-grade histology and worse prognosis among smokers","volume":"93","author":"Hayashi","year":"2002","journal-title":"Jpn J. Cancer Res"},{"issue":"10","key":"10.1016\/j.mrgentox.2025.503903_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/cells11101668","article-title":"Integrated Analysis of Cancer Tissue and Vitreous Humor from Retinoblastoma Eyes Reveals Unique Tumor-Specific Metabolic and Cellular Pathways in Advanced and Non-Advanced Tumors","volume":"11","author":"Babu","year":"2022","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.mrgentox.2025.503903_bib52","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/neuonc\/noab003","article-title":"PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma","volume":"23","author":"Wu","year":"2021","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.mrgentox.2025.503903_bib53","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13045-022-01367-4","article-title":"PARP1-MGMT complex underpins pathway crosstalk in O(6)-methylguanine repair","volume":"15","author":"Cropper","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.mrgentox.2025.503903_bib54","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/1471-2407-14-151","article-title":"Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide","volume":"14","author":"Tentori","year":"2014","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.mrgentox.2025.503903_bib55","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/1535-7163.MCT-14-0810","article-title":"MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide","volume":"14","author":"Erice","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"19","key":"10.1016\/j.mrgentox.2025.503903_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910687","article-title":"Poly ADP Ribose Polymerase Inhibitor Olaparib Targeting Microhomology End Joining in Retinoblastoma Protein Defective Cancer: Analysis of the Retinoblastoma Cell-Killing Effects by Olaparib after Inducing Double-Strand Breaks","volume":"22","author":"Jiang","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.mrgentox.2025.503903_bib57","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S1074-5521(96)90175-1","article-title":"Drug-related killings: a case of mistaken identity","volume":"3","author":"Karran","year":"1996","journal-title":"Chem. Biol."},{"issue":"5","key":"10.1016\/j.mrgentox.2025.503903_bib58","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ijc.10532","article-title":"Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model","volume":"100","author":"Middleton","year":"2002","journal-title":"Int J. Cancer"},{"issue":"4","key":"10.1016\/j.mrgentox.2025.503903_bib59","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/pbc.20803","article-title":"MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma","volume":"48","author":"Donson","year":"2007","journal-title":"Pedia Blood Cancer"},{"issue":"6","key":"10.1016\/j.mrgentox.2025.503903_bib60","first-page":"1107","article-title":"Effect of O(6)-methylguanine-DNA methyltransferase methylation in medulloblastoma","volume":"7","author":"Kurimoto","year":"2017","journal-title":"Mol. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.mrgentox.2025.503903_bib61","doi-asserted-by":"crossref","first-page":"a012609","DOI":"10.1101\/cshperspect.a012609","article-title":"Nucleotide excision repair in eukaryotes","volume":"5","author":"Scharer","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"10","key":"10.1016\/j.mrgentox.2025.503903_bib62","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ncb1172","article-title":"Targeted ubiquitination of CDT1 by the DDB1-CUL4A-ROC1 ligase in response to DNA damage","volume":"6","author":"Hu","year":"2004","journal-title":"Nat. Cell Biol."},{"issue":"15","key":"10.1016\/j.mrgentox.2025.503903_bib63","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/onc.2013.141","article-title":"Malignant melanoma cells acquire resistance to DNA interstrand cross-linking chemotherapeutics by p53-triggered upregulation of DDB2\/XPC-mediated DNA repair","volume":"33","author":"Barckhausen","year":"2014","journal-title":"Oncogene"},{"issue":"20","key":"10.1016\/j.mrgentox.2025.503903_bib64","doi-asserted-by":"crossref","first-page":"7918","DOI":"10.1158\/0008-5472.CAN-10-0161","article-title":"Nucleotide excision repair gene expression after Cisplatin treatment in melanoma","volume":"70","author":"Bowden","year":"2010","journal-title":"Cancer Res"},{"issue":"1-2","key":"10.1016\/j.mrgentox.2025.503903_bib65","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.canlet.2011.12.038","article-title":"Base excision repair and cancer","volume":"327","author":"Wallace","year":"2012","journal-title":"Cancer Lett."},{"key":"10.1016\/j.mrgentox.2025.503903_bib66","first-page":"10","article-title":"PA. Exploiting base excision repair to improve therapeutic approaches for pancreatic cancer","volume":"2","author":"McCarroll","year":"2015","journal-title":"Front Nutr."},{"issue":"3","key":"10.1016\/j.mrgentox.2025.503903_bib67","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ygeno.2007.05.002","article-title":"Identification of genes associated with tumorigenesis of retinoblastoma by microarray analysis","volume":"90","author":"Chakraborty","year":"2007","journal-title":"Genomics"},{"issue":"2","key":"10.1016\/j.mrgentox.2025.503903_bib68","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/bjc.2013.283","article-title":"Gene expression profiling identifies different sub-types of retinoblastoma","volume":"109","author":"Kapatai","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.mrgentox.2025.503903_bib69","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1136\/bjophthalmol-2013-304166","article-title":"Dysregulation of human apurinic\/apyrimidinic endonuclease 1 (APE1) expression in advanced retinoblastoma","volume":"98","author":"Sudhakar","year":"2014","journal-title":"Br. J. Ophthalmol."},{"issue":"3","key":"10.1016\/j.mrgentox.2025.503903_bib70","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s10637-012-9876-9","article-title":"A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors","volume":"31","author":"Gordon","year":"2013","journal-title":"Invest N. Drugs"},{"issue":"1","key":"10.1016\/j.mrgentox.2025.503903_bib71","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2011.135","article-title":"Removal of uracil by uracil DNA glycosylase limits pemetrexed cytotoxicity: overriding the limit with methoxyamine to inhibit base excision repair","volume":"3","author":"Bulgar","year":"2012","journal-title":"Cell Death Dis."},{"issue":"17","key":"10.1016\/j.mrgentox.2025.503903_bib72","doi-asserted-by":"crossref","first-page":"8350","DOI":"10.7150\/thno.51456","article-title":"Ligase 1 is a predictor of platinum resistance and its blockade is synthetically lethal in XRCC1 deficient epithelial ovarian cancers","volume":"11","author":"Ali","year":"2021","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.mrgentox.2025.503903_bib73","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-10864-3","article-title":"A Novel Benzocoumarin-Stilbene Hybrid as a DNA ligase I inhibitor with in vitro and in vivo anti-tumor activity in breast cancer models","volume":"7","author":"Hussain","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mrgentox.2025.503903_bib74","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1146\/annurev.biochem.74.082803.133243","article-title":"DNA mismatch repair","volume":"74","author":"Kunkel","year":"2005","journal-title":"Annu Rev. Biochem"},{"issue":"23","key":"10.1016\/j.mrgentox.2025.503903_bib75","first-page":"8158","article-title":"Mismatch repair-dependent transcriptome changes in human cells treated with the methylating agent N-methyl-n\u2032-nitro-N-nitrosoguanidine","volume":"63","author":"di Pietro","year":"2003","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.mrgentox.2025.503903_bib76","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1200\/JCO.2011.39.5590","article-title":"Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study","volume":"30","author":"Win","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.mrgentox.2025.503903_bib77","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa043146","article-title":"Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer)","volume":"352","author":"Hampel","year":"2005","journal-title":"N. Engl. J. Med"},{"issue":"10","key":"10.1016\/j.mrgentox.2025.503903_bib78","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1167\/iovs.03-1273","article-title":"Microsatellite instability and MLH1 promoter methylation in human retinoblastoma","volume":"45","author":"Choy","year":"2004","journal-title":"Invest Ophthalmol. Vis. Sci."},{"issue":"10","key":"10.1016\/j.mrgentox.2025.503903_bib79","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41416-019-0599-y","article-title":"Immune checkpoint inhibitors for the treatment of MSI-H\/MMR-D colorectal cancer and a perspective on resistance mechanisms","volume":"121","author":"Sahin","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.mrgentox.2025.503903_bib80","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s00262-020-02529-4","article-title":"Clinical relevance of the comparative expression of immune checkpoint markers with the clinicopathological findings in patients with primary and chemoreduced retinoblastoma","volume":"69","author":"Singh","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.mrgentox.2025.503903_bib81","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1167\/iovs.62.2.6","article-title":"Retinoblastoma Is Characterized by a Cold, CD8+ Cell Poor, PD-L1- Microenvironment, Which Turns Into Hot, CD8+ Cell Rich, PD-L1+ After Chemotherapy","volume":"62","author":"Miracco","year":"2021","journal-title":"Invest Ophthalmol. Vis. Sci."},{"issue":"18","key":"10.1016\/j.mrgentox.2025.503903_bib82","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184659","article-title":"PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score","volume":"13","author":"Cho","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.mrgentox.2025.503903_bib83","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev.biochem.052308.093131","article-title":"The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway","volume":"79","author":"Lieber","year":"2010","journal-title":"Annu Rev. Biochem"},{"issue":"1","key":"10.1016\/j.mrgentox.2025.503903_bib84","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1139\/bcb-2012-0058","article-title":"XRCC4 and XLF form long helical protein filaments suitable for DNA end protection and alignment to facilitate DNA double strand break repair","volume":"91","author":"Mahaney","year":"2013","journal-title":"Biochem Cell Biol."},{"issue":"2","key":"10.1016\/j.mrgentox.2025.503903_bib85","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41419-017-0203-4","article-title":"UHRF1 depletion sensitizes retinoblastoma cells to chemotherapeutic drugs via downregulation of XRCC4","volume":"9","author":"He","year":"2018","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.mrgentox.2025.503903_bib86","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/1878-0261.12607","article-title":"UHRF1 downmodulation enhances antitumor effects of histone deacetylase inhibitors in retinoblastoma by augmenting oxidative stress-mediated apoptosis","volume":"14","author":"Kim","year":"2020","journal-title":"Mol. Oncol."},{"issue":"5","key":"10.1016\/j.mrgentox.2025.503903_bib87","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1021\/acs.biochem.1c00698","article-title":"Discovery and Mechanism of Small Molecule Inhibitors Selective for the Chromatin-Binding Domains of Oncogenic UHRF1","volume":"61","author":"Liu","year":"2022","journal-title":"Biochemistry"},{"key":"10.1016\/j.mrgentox.2025.503903_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106616","article-title":"Inhibitors of UHRF1 base flipping activity showing cytotoxicity against cancer cells","volume":"137","author":"Ciaco","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.mrgentox.2025.503903_bib89","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jtho.2020.08.024","article-title":"UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma","volume":"16","author":"Reardon","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"42","key":"10.1016\/j.mrgentox.2025.503903_bib90","doi-asserted-by":"crossref","first-page":"44289","DOI":"10.18632\/oncotarget.6247","article-title":"The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo","volume":"6","author":"Vendetti","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.mrgentox.2025.503903_bib91","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","article-title":"The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models","volume":"19","author":"Wengner","year":"2020","journal-title":"Mol. Cancer Ther."},{"issue":"12","key":"10.1016\/j.mrgentox.2025.503903_bib92","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2012.181","article-title":"Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation","volume":"3","author":"Fokas","year":"2012","journal-title":"Cell Death Dis."},{"issue":"8","key":"10.1016\/j.mrgentox.2025.503903_bib93","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/1535-7163.MCT-20-1026","article-title":"Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents","volume":"20","author":"Jo","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"27","key":"10.1016\/j.mrgentox.2025.503903_bib94","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1200\/JCO.19.02404","article-title":"Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors","volume":"38","author":"Yap","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.mrgentox.2025.503903_bib95","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1200\/JCO.2017.76.6915","article-title":"Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors","volume":"36","author":"Thomas","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.mrgentox.2025.503903_bib96","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1136\/ijgc-2021-002973","article-title":"ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT\/GYN1\/NCRI)","volume":"31","author":"Banerjee","year":"2021","journal-title":"Int J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.mrgentox.2025.503903_bib97","first-page":"130","article-title":"DNA double strand break repair via non-homologous end-joining","volume":"2","author":"Davis","year":"2013","journal-title":"Transl. Cancer Res"},{"key":"10.1016\/j.mrgentox.2025.503903_bib98","article-title":"A cell cycle-dependent BRCA1-UHRF1 cascade regulates DNA double-strand break repair pathway choice","volume":"7","author":"Zhang","year":"2016","journal-title":"Nat. Commun."},{"issue":"47","key":"10.1016\/j.mrgentox.2025.503903_bib99","article-title":"Bioinformatics analysis of multi-omics data identifying molecular biomarker candidates and epigenetically regulatory targets associated with retinoblastoma","volume":"99","author":"Zeng","year":"2020","journal-title":"Med. (Baltim. )"},{"issue":"7","key":"10.1016\/j.mrgentox.2025.503903_bib100","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/bjo-2023-323388","article-title":"Subset of retinoblastoma tumours is associated with BRCA1\/2 mutations","volume":"108","author":"Kim","year":"2024","journal-title":"Br. J. Ophthalmol."},{"issue":"31","key":"10.1016\/j.mrgentox.2025.503903_bib101","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1038\/s41388-020-1372-7","article-title":"Functional genomics identifies new synergistic therapies for retinoblastoma","volume":"39","author":"Aubry","year":"2020","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.mrgentox.2025.503903_bib102","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/s41419-021-03805-6","article-title":"BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair","volume":"12","author":"Zhang","year":"2021","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.mrgentox.2025.503903_bib103","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13058-020-01354-y","article-title":"Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer","volume":"22","author":"Garrido-Castro","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"2","key":"10.1016\/j.mrgentox.2025.503903_bib104","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cell.2010.03.012","article-title":"53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks","volume":"141","author":"Bunting","year":"2010","journal-title":"Cell"},{"issue":"7553","key":"10.1016\/j.mrgentox.2025.503903_bib105","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nature14328","article-title":"REV7 counteracts DNA double-strand break resection and affects PARP inhibition","volume":"521","author":"Xu","year":"2015","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.mrgentox.2025.503903_bib106","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1038\/s41467-021-23463-8","article-title":"Poltheta inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance","volume":"12","author":"Zatreanu","year":"2021","journal-title":"Nat. Commun."},{"issue":"42","key":"10.1016\/j.mrgentox.2025.503903_bib107","doi-asserted-by":"crossref","first-page":"17041","DOI":"10.1073\/pnas.1305170110","article-title":"Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance","volume":"110","author":"Johnson","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.mrgentox.2025.503903_bib108","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/path.4140","article-title":"Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor","volume":"229","author":"Barber","year":"2013","journal-title":"J. Pathol."},{"issue":"17","key":"10.1016\/j.mrgentox.2025.503903_bib109","doi-asserted-by":"crossref","first-page":"8898","DOI":"10.1093\/nar\/gky657","article-title":"Loss of E2F7 confers resistance to poly-ADP-ribose polymerase (PARP) inhibitors in BRCA2-deficient cells","volume":"46","author":"Clements","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.mrgentox.2025.503903_bib110","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/s41467-020-16096-w","article-title":"Ubiquitinated-PCNA protects replication forks from DNA2-mediated degradation by regulating Okazaki fragment maturation and chromatin assembly","volume":"11","author":"Thakar","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mrgentox.2025.503903_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2021.103209","article-title":"Revisiting the BRCA-pathway through the lens of replication gap suppression: \"Gaps determine therapy response in BRCA mutant cancer\"","volume":"107","author":"Cantor","year":"2021","journal-title":"DNA Repair (Amst. )"},{"issue":"20","key":"10.1016\/j.mrgentox.2025.503903_bib112","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14205124","article-title":"Enhanced Epithelial-to-Mesenchymal Transition and Chemoresistance in Advanced Retinoblastoma Tumors Is Driven by miR-181a","volume":"14","author":"Suresh Babu","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.mrgentox.2025.503903_bib113","first-page":"1655","article-title":"Expression of multidrug resistance proteins in retinoblastoma","volume":"10","author":"Shukla","year":"2017","journal-title":"Int J. Ophthalmol."},{"issue":"6","key":"10.1016\/j.mrgentox.2025.503903_bib114","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/1440-1681.13279","article-title":"Hypoxia-induced lncRNA ANRIL promotes cisplatin resistance in retinoblastoma cells through regulating ABCG2 expression","volume":"47","author":"Yin","year":"2020","journal-title":"Clin. Exp. Pharm. Physiol."},{"issue":"1","key":"10.1016\/j.mrgentox.2025.503903_bib115","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/jnci\/94.1.26","article-title":"Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma","volume":"94","author":"Esteller","year":"2002","journal-title":"J. Natl. Cancer Inst."}],"container-title":["Mutation Research - Genetic Toxicology and Environmental Mutagenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1383571825000622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1383571825000622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T15:49:28Z","timestamp":1773848968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1383571825000622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":115,"alternative-id":["S1383571825000622"],"URL":"https:\/\/doi.org\/10.1016\/j.mrgentox.2025.503903","relation":{},"ISSN":["1383-5718"],"issn-type":[{"value":"1383-5718","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The potential implications of dysregulated DNA damage repair genes and their modulators as adjuvants for current chemotherapy regimens in Retinoblastoma tumors","name":"articletitle","label":"Article Title"},{"value":"Mutation Research - Genetic Toxicology and Environmental Mutagenesis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mrgentox.2025.503903","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"503903"}}